N@N

Halozyme Therapeutics Names Matt Posard to Board of Directors

^{Published on 2013-03-28 13:33:10 - Market Wire}
 

Halozyme Therapeutics Names Matt Posard to Board of Directors -- SAN DIEGO, March 28, 2013 /PRNewswire/ --

[ ]

[ Download image ]

SAN DIEGO, March 28, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: [ HALO ]) today announced the appointment of Matt Posard to its Board of Directors.  Mr. Posard is currently Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina, Inc.

(Logo: [ http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ])

"We welcome Matt to our Board of Directors. His strategic marketing experience will complement Halozyme's Board well as we increase our commercial activities with Hylenex," said Gregory I. Frost , Ph.D., President and Chief Executive Officer at Halozyme.

Mr. Posard has over two decades of experience in strategic and product marketing. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina's successful commercial entry into the life science sequencing market where it now holds significant market share alongside the company's array business. Prior to joining Illumina, he held a variety of positions with the product marketing team at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. He also oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company's BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter . Mr. Posard holds a Bachelor of Arts degree in Quantitative Economics and Decision Science from the University of California, San Diego.

About Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma, Intrexon, and Pfizer. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at [ www.halozyme.com ].

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
[ ir@halozyme.com ]

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
[ Nurha.Hindi@hkstrategies.com ]

SOURCE Halozyme Therapeutics, Inc.